Phanes Therapeutics Announces FDA IND Clearance for PT217, an Anti-DLL3/Anti-CD47 Bispecific Antibody Being Developed for Patients with Small Cell Lung Cancer and Other Neuroendocrine Cancers

Phanes Therapeutics, Inc., a clinical stage biotech company focused on oncology, announced that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody.